Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...
Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...
JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating ...
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome ...
Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...
Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results